These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21495800)

  • 21. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates.
    Hill MJ; McWilliams GD; Miller KA; Scott RT; Frattarelli JL
    Fertil Steril; 2009 Mar; 91(3):739-43. PubMed ID: 18314123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a luteal estradiol patch and a gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation for in vitro fertilization in poor responders.
    Dragisic KG; Davis OK; Fasouliotis SJ; Rosenwaks Z
    Fertil Steril; 2005 Oct; 84(4):1023-6. PubMed ID: 16213865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
    Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of GnRH antagonists and flareup GnRH agonists in donor oocyte cycles.
    Wei AY; Mijal KA; Christianson MS; Schouweiler CM; Lindheim SR
    J Reprod Med; 2008 Mar; 53(3):147-50. PubMed ID: 18441715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth Hormone Supplementation in the Luteal Phase Before Microdose GnRH Agonist Flare Protocol for In Vitro Fertilization.
    Dunne C; Seethram K; Roberts J
    J Obstet Gynaecol Can; 2015 Sep; 37(9):810-815. PubMed ID: 26605451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization. Does It Improve IVF Outcomes in Poor Responders as Compared to Oral Contraceptive Pill?
    Elassar A; Nulsen J; Engmann L; Benadiva C
    J Reprod Med; 2015; 60(5-6):199-204. PubMed ID: 26126304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles.
    Lee JR; Choi YS; Jee BC; Ku SY; Suh CS; Kim KC; Lee WD; Kim SH
    Fertil Steril; 2007 Nov; 88(5):1344-9. PubMed ID: 17548083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization.
    Chang EM; Han JE; Won HJ; Kim YS; Yoon TK; Lee WS
    J Assist Reprod Genet; 2012 Mar; 29(3):225-30. PubMed ID: 22160464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists.
    Chung K; Krey L; Katz J; Noyes N
    Fertil Steril; 2005 Aug; 84(2):313-8. PubMed ID: 16084870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of the young poor responder: comparison of the luteal estradiol/gonadotropin-releasing hormone antagonist priming protocol versus oral contraceptive microdose leuprolide.
    Shastri SM; Barbieri E; Kligman I; Schoyer KD; Davis OK; Rosenwaks Z
    Fertil Steril; 2011 Feb; 95(2):592-5. PubMed ID: 21074154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of estradiol and progesterone priming/antagonist/letrozole and microdose flare-up protocols for poor responders undergoing intracytoplasmic sperm injection.
    Yucel O; Ekin M; Cengiz H; Zebitay AG; Yalcinkaya S; Karahuseyinoglu S
    Gynecol Endocrinol; 2014 Sep; 30(9):653-6. PubMed ID: 24850255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
    Ye H; Huang G; Pei L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist.
    Var T; Tonguc E; Dogan M; Mollamahmutoglu L
    Gynecol Endocrinol; 2011 Aug; 27(8):558-61. PubMed ID: 20642381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Application of GnRH-antagonist to IVF-ET for patients with poor ovarian response].
    Wang B; Sun HX; Hu YL; Chen H; Zhang NY
    Zhonghua Nan Ke Xue; 2008 May; 14(5):423-6. PubMed ID: 18572861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.